Medtronic plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDT research report →
About the company
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software.
- CEO
- Geoffrey Straub Martha
- IPO
- 1973
- Employees
- 95,000
- HQ
- Galway, US
Price Chart
- Market Cap
- $106.49B
- P/E
- 22.18
- P/S
- 2.93
- P/B
- 2.16
- EV/EBITDA
- 13.63
- Div Yield
- 3.43%
- Gross Margin
- 65.02%
- Op Margin
- 17.78%
- Net Margin
- 13.20%
- ROE
- 9.85%
- ROIC
- 6.13%
- Revenue
- $36.36B · 8.43%
- Net Income
- $4.80B · 2.96%
- EPS
- $3.75 · 3.31%
- Op Income
- $6.47B
- FCF YoY
- 4.65%
- 52W High
- $106.33
- 52W Low
- $73.31
- 50D MA
- $79.05
- 200D MA
- $91.33
- Beta
- 0.60
- Avg Volume
- 10.34M
Get TickerSpark's AI analysis on MDT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Thompson Kweli | other | 0 |
| Jun 18, 26 | Thompson Kweli | other | 3,252.987 |
| Jun 18, 26 | Thompson Kweli | other | 9,178.809 |
| Aug 1, 17 | Thompson Kweli | other | 1,704 |
| Jan 30, 18 | Thompson Kweli | other | 1,608 |
| Jul 31, 18 | Thompson Kweli | other | 4,407 |
| Jul 30, 19 | Thompson Kweli | other | 6,271 |
| Jul 29, 20 | Thompson Kweli | other | 1,615 |
| Aug 3, 21 | Thompson Kweli | other | 10,181 |
| Aug 2, 22 | Thompson Kweli | other | 6,358 |
Our MDT coverage
Recent articles, reports, and earnings notes.
Medtronic (MDT): Broad-Based Growth Is Finally Accelerating
Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Medtronic plc (MDT) rises 5.9% on strong earnings outlook
Medtronic plc (MDT) rises after reporting fiscal Q4 2026 results that showed stronger revenue growth, standout cardiovascular performance, and upbeat FY27 guidance. Investors are responding to a cleaner growth narrative as the medical device giant signals improving momentum and solid cash generation.
Medtronic may have finally found its second act
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Want a deeper read on MDT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.